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Copy number variations (CNV) have an important role in etiology of 
 neurodevelopmental disorders (NDD). Among them, individuals with attention-
deficit and hyperactivity disorders (ADHD) have 1.33 times higher overall rate of 
CNVs larger than 100 kb compared to healthy controls. These CNVs are often shared 
with other NDDs and neuropsychiatric disorders such as schizophrenia (SCZ) and 
autism spectrum disorder (ASD), although duplications of 15q13.3 and 16p13.11 
have been found enriched in ADHD cohorts. CNVs provide new opportunities for 
studying and management of psychiatric disorders including ADHD. Therefore this 
chapter provides a brief overview of the literature on this topic and presents the 
benefits of CNV genetic diagnostics in ADHD patients.
Keywords: attention-deficit and hyperactivity disorders (ADHD), neuropsychiatric 
disorders, neurodevelopmental disorders (NDDs), copy number variations (CNV), 
chromosomal microarrays (CMA), whole genome sequencing (WGS)
1. Introduction
Attention-deficit and hyperactivity disorders (ADHD) is a childhood-onset 
neuropsychiatric disorder affecting 5–6% of children [1]. The follow-up studies 
of children with ADHD showed that symptoms are evident even in adulthood in 
approximately two-third of patients [2] and that disorder is present in 2.5% of adults 
[1, 3]. The twin studies suggest a high heritability of ADHD, estimated to be at 
approximately 70% [4]. This is comparable to the heredity of other neuropsychiatric 
disorders, such as autism spectrum disorder (ASD) and schizophrenia (SCZ) [5]. 
Genetic studies shown a complex genetic etiology comprising both common vari-
ants such are single nucleotide polymorphisms (SNPs) [6], as well as rare variants 
causing a loss-of-function in single gene in form of single nucleotide variants (SNVs) 
[7], and deletions or duplications of multiple genes in form of copy number varia-
tions (CNVs) [8–10]. A SNP-based genome wide heritability studies can explain the 
genetic origin of the ADHD in approximately 22% cases, which still does not explain 
the large proportion of heredity set out in twin studies [6]. To some extent the 
 difference can be explained by rare variants in form of SNVs and CNVs [11].
In 2010, a chromosomal microarrays (CMA) which are used for detection 
of genomic CNVs, became first-tier clinical diagnostic test for individuals with 
developmental delay and/or intellectual disability (DD/ID), ASD, and/or multiple 
congenital anomalies. Namely, a review of 33 studies including 21,698 patients 
tested by CMA showed that a pathogenic CNV could be determined in an average 
of 12.2% patients across all studies [12]. Since then, rare CNVs have been described 
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across different neurodevelopmental disorders (NDDs) [13]. In individuals with 
ADHD a 1.33 times higher overall rate of CNVs larger than 100 kb compared to the 
healthy controls was observed [14].
Therefore, an important role of CNVs in etiology of ADHD is further discussed 
in this chapter.
2. What are CNVs?
CNVs are genomic structural variations causing the deletion or duplication 
of coding and non-coding segments of DNA. They vary in size, spanning from 
single gene to encompassing multiple genes. They can be common or rare events in 
genome acting as a disease cause.
CNVs occur in genome due to the segmental duplications present in certain regions 
in human genome. These repetitive sequences represent CNV “hotspots” as they make 
these regions prone to mutational mechanism called non-allelic homologs recombina-
tion. The process occurs during sperm or egg formation, therefore CNV prevalence 
remains relatively constant regardless of the severity of genomic disorder [15].
The CMA technology was designed to detect deletions and duplications across 
human genome randomly, without the need of specific suspected diagnosis of 
genomic disorder made by clinician. The technology enables us to identify the recur-
rent as well as novel disease associated CNVs [15]. Rare CNVs have been described as 
microdeletions or microduplications involved in many NDDs [12, 16–20].
Rare CNVs are considered to be present in less than <0.1% of general popula-
tion. Disease associated CNVs are rare but collectively explain approximately 20% 
of DD/ID, 10% of ASD, and 5% of SCZ cases. However for other neuropsychiatric 
conditions the role of rare CNVs in disease pathophysiology is less clear, therefore 
diagnostics yield for CMA remains to be determined [17].
An important role in prevalence of rare CNV has its relative overall penetrance. 
CNVs with high overall penetrance are expected to be absent from general popula-
tion whereas low penetrance CNVs have higher chance to be found in general 
population, where CNV carriers may have mild clinical manifestation [21, 22].
Different NDDs also share same CNVs effecting the same genes [4, 17] indicat-
ing on their clinical pleiotropy [13].
3. Role of CNVs in ADHD
ADHD has a complex genetic architecture. The larger sample size and advances 
in technology enabled to study an effect of different classes of genetic variations 
in disease development. This revealed that ADHD is polygenic disorder like other 
neuropsychiatric disorders and its genetic architecture involves both the thousands 
of common variants with individually small effect size (SNPs), as well as rare 
variants causing a loss-of-function in single gene (SNVs) or small or larger genome 
deletions or duplications (CNVs) [23]. From all the genetic variants that contribute 
to etiology of ADHD, CNVs probably have the most evident clinical evidence, since 
they are enriched in several neuropsychiatric disorders [15].
ADHD is often associated with syndromic disorders [5]. For example, ADHD 
symptoms are present in more than 60% of patients with Williams-Beuren syndrome 
caused by microdeletion of chromosome region 7q11.23 [24] and  approximately 40% 
patients with 22q11 deletion syndrome, also known as DiGeorge syndrome [25].
A parent-offspring trio studies showed a higher rate of de novo CNVs in children 
with NDDs. The highest is observed in 10% of children with ID/DD [26]. For ASD 
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patients a 3- to 5-fold higher rate is observed than in control [27]. Similar rate 
was observed in SCZ-trio studies [28]. Only recently, studies of ADHD patients 
have reached the number of patients, which would unable similar studies to be 
performed as in ASD and SCZ patients [5]. Most recent trio-based study of ADHD 
patients have shown that overall mutation rate of de novo CNVs was 4.6% and 
similar to the rate observed in children with ADS, but slightly higher than in SCZ 
study [29]. Their rate was also higher than from previously trio-based ADHD study, 
which was 1.7% [30]. From the 14 de novo CNVs found in 13 ADHD probands, four 
CNVs: duplications of 15q13.1, 16p13.11 and 22q11.21 and deletion of 16p12.1, have 
been previously implicated in neuropsychiatric disorders or NDDs, once again 
highlighting their clinical pleiotropy [29].
In the study of Gudmundsson et al., a presence of 19 rare neuropsychiatric CNVs, 
that confer risk of ASD and SCZ, have been tested in 8883 ADHD probands. Presence 
was confirmed in 2.15% of individuals, compared to the 0.86% of controls. Only one 
CNV carrier had comorbid diagnosis of ADHD and ASD, and none for SCZ. Eight 
of the tested CNVs were significantly associated with ADHD risk: deletion of 2p16.3 
(NRXN1), 15q11.2, 15q13.3, and 22q11.21 and duplications of 1q21.1 distal, 16p11.2 
proximal, 16p13.11, and 22q11.21 [10]. Among them, deletion of DiGeorge region 
(22q11 deletion) was established to have highest risk of ADHD, since in addition to 
high frequency of SCZ in DiGeorge patients, ADHD has been observed in 37% of the 
children [31]. A high significance to ADHD was also confirmed for 15q13.3 deletion. 
Deletions of this region is associated with various NDDs [32] with the higher rate of 
neuropsychiatric disorders, along with 6.5% of ADHD [3, 33].
3.1 Does ADHD-specific CNVs exist?
There is still no ADHD-specific CNV identified. Although, there are still some 
incocistency about frequency of rare CNVs in ADHD patients [30, 34–38], studies 
of CNVs in ADHD patients show a higher burden of this structural variants com-
pared to the control [8, 9, 30, 39, 40].
The CNVs found in patients with ADHD often coincide with ASD and SCZ 
chromosomal loci [41–43], which is also evident in clinical comorbidity of ADHD 
with this two disorders [44]. Stronger comorbidity is set for ASD [45] by common 
CNV-affected genes [8, 9, 30] and biological pathways [46]. Overlap of the disease-
associated genes between ASD and ADHD was also observed in SNVs studies [7].
A large genome-wide CNV analysis was performed recently in 2691 patients 
diagnosed with different NDDs, in order to determine the pleiotropy of CNVs. For 
example, genes like NRXN1, EXOC3, and PCMTD2 were found in ASD, ADHD 
and SCZ or ASD, ADHD and obsessive compulsive disorder (OCD) or ASD, OCD 
and SCH patients respectively. Recurrent and non-recurrent CNV regions were also 
identified to be involved in multiple NDDs, as 16p13.11 and 15q11-q13 duplications 
in SCZ, OCD, ASD and ADHD. The study also showed that clinically relevant CNV 
was detected in 9.4% (N 40/427) ADHD patients, similar to the percentage in ASD 
(11.4%) and SCZ (10.8%) patients [13]. Studies like this show an importance of 
CNVs in genetics of NDDs and complex genetic architecture of this disorders.
Interestingly, not much has been done in studying the CNVs implicated in ID/
DD, since ADHD patients who have comorbid ID/DD are usually exclude from such 
studies [23].
A recent study of CNV involved genes obtained from 11 published studies was 
performed with aim to define ADHD-associated candidate genes. Among 2241 local-
ized genes from 1532 CNVs, 26 genes were established to have highest credibility 
as ADHD candidate genes. This genes also share common biological topic such as 
transcription, mitochondrial biology, mRNA metabolism, and cytoskeleton [47].
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3.2 Ambiguity of the rare CNVs
By researching of the genome and CNV mapping, it was estimated that sequence 
included in CNVs contribute to the 4.8–9.5% of the genome. Additionally, it was pos-
tulated that about 100 genes can be deleted by CNVs and have no apparent phenotype 
[19]. Furthermore, an average mutation rate in individuals in the general population 
should be take into account, consequently rare variants could be false positive [48].
Therefore, the meaning of a rare unknown CNV identified in ADHD patient 
should be carefully interpreted.
4. The importance of CNV in diagnostics of ADHD
Reaching the genetic diagnosis in ADHD patient can have many advantages for 
the patient as well as clinician. Molecular diagnosis can benefit in patients’ care in 
management and treatment (e.g. preference or avoidance of particular medica-
tions) as well as prognosis [15].
Genetic counseling is also important. The family based and twin studies of 
ADHD patients revealed a strong familial and genetic overlap of ADHD with ASD 
and ID. The individuals with monozygotic twin with ASD have an increased risk for 
ADHD compared to the risk observed in dizygotic twin studies. The association is 
higher for higher-functioning than lower-functioning ASD [23]. Siblings of ADHD 
probands have ninefold higher risk to ADHD compared to the siblings in controls 
[49]. ADHD is also strongly associated with lower IQ and ID indicating that they 
share heritability [23]. Additionally, family members of ADHD individuals are at 
elevated risk for neurodevelopmental and neuropsychiatric disorders. Knowing the 
genetic cause may have an impact on their management and treatment [23].
CNVs will lead to understanding how genes affect biological pathways involved 
in ADHD. For example, CNVs in glutameric genes were liked to cognitive and 
clinical impairments of ADHD [4]. In study of Thapar et al. found CNVs in ADHD 
patients were enriched in genes for which it was previously known to be involved in 
SCZ, Fragile X ID, and partly with autism [50]. More recently 26 ADHD-associated 
candidate genes were identified that share common biological topic such as tran-
scription, mitochondrial biology, mRNA metabolism, and cytoskeleton [47].
Other features can be explain by CNVs. The duplications of CHRNA7 gene were 
observed in higher rate in ADHD patients [9]. This gene encodes alpha-7 nicotinic 
acetylcholine receptor. A higher rate of smokers have been observed in ADHD 
patients [51]. Namely, nicotine administration reduce hyperactivity and impulsivity 
[52] since nicotine modulates dopaminergic neurons by interacting with nicotinic 
acetylcholine receptors [53].
Moreover, knowledge of the cause of the disease assist in better understanding 
and felicitate the acceptance of the condition, improves genetic counseling and also 
refine possible future new treatments [15].
Although there are still no clear guidelines when to perform genetic testing for 
rare variants in ADHD patients, testing for CNVs is recommended in individuals 
with comorbid mild ID or ASD [23].
5. Future prospects
Technologies such as whole genome sequencing (WGS) that enable us to detect 
SNVs as well as structural variants in the genome in a single experiment, will 
facilitate the detection of even smaller CNVs, which we could not detect with CMA 
due to technology limitations.
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Pathogenicity of rare large CNVs in NDDs and neuropsychiatric disorders is 
mostly defined, whereas a significance of a small nonrecurrent CNVs (<500 kb) is 
still ambiguous. In the study of 4417 patients referred to CMA testing 383 (8.67%) 
patient had at least one small, nonrecurrent CNV. Of these, 142 (3.21%) patients 
were carriers of pathogenic or likely pathogenic CNV, from which in 80 patients a 
single gene or exonic deletion of the gene was found [54].
A CNV study in adult ADHD patients did not found enrichment for large CNVs, 
however they did found significant increase of small CNVs [14]. Therefore, the 
relevance of new technologies in studying of genomic disorders will facilitate new 
genotype–phenotype correlation [15].
6. Conclusions
CNVs provide new opportunities for studying and management of psychiatric 
disorders including ADHD.
Detection of small CNVs of few kilo base in size is still difficult due to method 
limitations, although WGS of the ADHD patients promises their discovery. On the 
other hand, for the detection of large rare CNVs that occurs with frequency less 
than 1%, large sample size are needed [5].
Furthermore, parent-offspring trio studies of de novo CNVs and SNVs will 
contribute in disease etiology, since de novo aberrations in genome are more likely 
deleterious [28]. Identification of disease-associated genes and knowledge of their 
molecular functions will lead to better understanding of their disease pathology 
and hopefully enable better diagnostic and treatment [47].
Genetic counseling for polygenic disorders with complex genetic architecture 
as is ADHD is challenging, due to variable phenotypic outcomes and incomplete 
penetrance encountered in majority of genetic disorders. Therefore understanding 
the molecular etiology for clinicians is useful in patient management, in terms of 
improving risk predictions, screening for extra-psychiatric features, treatment, etc. 
[15]. New discoveries are also a starting point for identifying and assessing novel 
treatments in ADHD patients [23].
Though psychiatric genetics is unlikely to change the treatment of patients, it 
will eventually contribute to more personalized medicine [5]. Therefore the role of 
CNVs in clinical practice for ADHD patients remains to be seen.
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